Bioqube Ventures
Bioqube Ventures is a venture capital firm based in Brussels, Belgium, focused on early-stage investments in the life sciences sector. Established in 2016, the firm primarily targets European biotech companies that are developing innovative therapeutic assets and technologies, with a particular emphasis on the Benelux region, France, and Germany. Bioqube Ventures operates through its independent fund, which supports both traditional investments in initial funding rounds and specialized "Create" projects that require additional de-risking before launching new ventures. The firm employs a hands-on approach, leveraging the expertise of a diverse team of fund managers, sector specialists, and experienced entrepreneurs to guide their portfolio companies towards growth. Bioqube Ventures does not currently invest in medtech, healthtech, or diagnostics.
Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.
Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.
Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.
Primmune Therapeutics, Inc., a biotechnology company, develops small molecule orally administered toll-like receptor 7 (TLR7) agonist to stimulate innate immunity in cancer immunotherapy. It offers TLR7 agonist for systemic activation of innate immunity. The company’s TLR7 is an agonist for acute and chronic viral infection. The company was founded in 2017 and is based in San Diego, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.